Lowest Price Guaranteed From USD 1,899
Published
February 2023
Slides
174
View Count
3923
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
Digital health is a broad concept that encompasses telemedicine, teleconsultation, remote monitoring, connected devices, digital health platforms and health applications. The outbreak of COVID-19 pandemic has propelled the usage of digital technologies in order to receive healthcare, remotely. The revolutionary developments in digital health have transformed medicine and biomedical science as well as promoted early disease diagnosis and treatment. In addition, several FemTech startups are focused on the development of products or offering services to women of all age groups dealing with issues related to pregnancy, periods and menopause. Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the women’s digital health domain have witnessed a surge in the investment activity, with capital investments worth more than USD 3 billion over the past few years. This has enabled the overall FemTech business to flourish. It is worth noting that, NC° Birth Control, developed by Natural Cycles, was the first application to receive approval from US FDA in 2018 and is CE marked in Europe. This application can be used as a method of contraception and to track menstrual cycles, regularly. Subsequently, in 2021, various other women’s digital health solutions received US FDA approvals, including Ava Fertility Tracker (first approved fertility tracking wearable) and Clue (period tracking and birth control app).
Currently, more than 200 women’s digital health solutions, including applications / software, wearable devices, and services have been marketed / are under development with applications across various therapeutic areas including, reproductive health / fertility, menstrual cycle, general wellness, pelvic care and fetal health. These digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population. In addition, by advocating more personalized and meaningful treatment for women, employers may advance health equity and aid in the eradication of healthcare inequities. Given the increasing research efforts and active involvement of investors, we anticipate the development of a variety of applications and devices focused on improving women’s health, in the coming years. Further, taking into consideration both the historical and contemporary scenarios, we believe that the women’s digital health market presents lucrative investment opportunities for both short and long term investors.
Scope of the Report
The Investor Series: Opportunities in Women’s Digital Health Market (Focus on Innovator Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Key Acquisition Targets, Business Risk Assessment and Return on Investments) report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:
One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with the women’s digital health market, over the coming decades. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity within the women’s digital health market have further been segmented across type of solution (applications / software, devices and services), therapeutic application area (fetal health, general wellness, menstrual cycle, pelvic care and reproductive health / fertility), and geography (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
EXCEL DELIVERABLE
Spreadsheet I includes details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. In addition, the deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated.
Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights related to the capital investments made in the women’s digital health domain (since 2011).
Spreadsheet III is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies’ dataset.
Spreadsheet IV is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the women’s digital health market.
Spreadsheet V includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on the likely return on investments received by the mentioned investors.
POWERPOINT DELIVERABLE
Chapter 1 provides a brief summary of the content presented in the report, beginning with the trends associated with the rapidly growing women’s digital health market. Further, some of the key benefits associated with women’s digital health solutions, have been presented. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.
Chapters 2 and 3 feature brief (pictorial) summaries of the project objectives and approach used for data collection and analysis, in this study.
Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.
Section I: Introduction to Women’s Digital Health Solutions and Innovator Landscape
Chapter 5 presents an introduction to women’s digital health, highlighting the background about the origin and evolution of this domain, along with benefits of digital health technologies. It features the key application areas of the FemTech industry, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. Further, it includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives of key stakeholder companies (as stated in publicly available articles and validated through primary research). It concludes with a discussion on the prominent barriers to the development and success of women’s digital health solutions.
Chapter 6 focuses on some of the innovators (companies established post-2006) and features detailed analysis of such companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.
Chapter 7 includes information on the various products / solutions offered by the companies captured in the report (listed in Chapter 6). Further, it features analysis based on number and types of products.
Chapter 8 presents a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity and estimated revenues and profits) of the different innovator companies, based on the insights obtained from product landscape.
Chapter 9 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely product-related value, value to patients, developer value and outreach-related value we developed an empirical framework to quantify the value proposition of a business.
Chapter 10 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developers of women’s digital health solutions captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing and valuation exercise.
Section II: Analysis of Investments
Chapter 11 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report.
Section III: Financial Analysis of Key Public Ventures
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall women’s digital health market from a financial perspective and includes detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of publicly listed companies within the innovator landscape dataset.
Chapter 13 includes detailed profiles of the public ventures engaged in the development of women’s digital health solutions. Each profile features a brief overview of the company, details on its management team, insight from its balance sheet (if available), information on product / service portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).
Section IV: Market Forecast and Opportunity Analysis
Chapter 14 features an insightful market forecast and opportunity analysis, highlighting the estimated current and future size of the overall women’s digital health market, during the period 2023-2035. The opportunity has been segregated on the basis of type of solution (applications / software, devices and services), therapeutic application area (fetal health, general wellness, menstrual cycle, pelvic care and reproductive health / fertility), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).
Section V: Key Acquisition Targets, Business Risk Assessment and Return on Investments
Chapter 15 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.
Chapter 16 includes a case study on business risk assessment, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, financial / asset-related risks, product / technology risks and other risks.
Chapter 17 includes a case study wherein the investors have exited various women’s digital health-based ventures, offering insights on return on investments received (based on availability of data). The abovementioned estimates / details offer a perspective on how past investments have paid off for investors as company gradually went public, over time.
Chapter 18 provides a pictorial summary of the overall project, presenting insights on the market landscape, funding and investment activity, value proposition, key acquisition targets and the market opportunities in women’s digital health domain, across different global regions.
Chapter 19 is a set of appendices, that contains the table of contents, list of figures, tables, companies and organizations mentioned in the report.
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovator Landscape
1.3. Product Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI – AVII Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Capital Investments in Women’s Digital Health
2.2. Summary Dashboard
2.3. AI – AIV Appendices
3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
4. MARKET FORECAST AND OPPORTUNITY ANALYSIS
4.1. Market Forecast and Opportunity Analysis: Summary
4.2. Market Forecast and Opportunity Analysis: Marketed Products Dataset
4.3. Market Forecast and Opportunity Analysis: Pricing Dataset
4.4. Market Forecast and Opportunity Analysis: Applications / Software (Base Scenario)
4.5. Market Forecast and Opportunity Analysis: Applications / Software (Conservative Scenario)
4.6. Market Forecast and Opportunity Analysis: Applications / Software (Optimistic Scenario)
4.7. Market Forecast and Opportunity Analysis: Devices (Base Scenario)
4.8. Market Forecast and Opportunity Analysis: Devices (Conservative Scenario)
4.9. Market Forecast and Opportunity Analysis: Devices (Optimistic Scenario)
4.10. Market Forecast and Opportunity Analysis: Services (Base Scenario)
4.11. Market Forecast and Opportunity Analysis: Services (Conservative Scenario)
4.12. Market Forecast and Opportunity Analysis: Services (Optimistic Scenario)
4.13. Market Forecast and Opportunity Analysis: Prevalence
4.14. Market Forecast and Opportunity Analysis: Validation
4.15. Market Forecast and Opportunity Analysis: Population Data
4.16. Market Forecast and Opportunity Analysis: UN World Population Data
5. RETURN ON INVESTMENTS
5.1. Analysis Notes
5.2. Estimated RoI for Investors in Company A
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT OBJECTIVES
3. PROJECT APPROACH
4. EXECUTIVE SUMMARY
Section I: Introduction to Women’s Digital Health Solutions and Innovator Landscape
5. THE WOMEN’S DIGITAL HEALTH MARKET
5.1. Overview
5.2. Importance of FemTech Industry
5.3. Digital Solutions focused on Women’s Health
5.4. Leading Products in Women’s Digital Health
5.5. Challenges in Women’s Digital Health
6. WOMEN’S DIGITAL HEALTH: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Women’s Digital Health Market
6.3. Analysis of Innovator Landscape
6.4. Concluding Remarks
7. WOMEN’S DIGITAL HEALTH: PRODUCT LANDSCAPE
7.1. List of Products: Information on Current Status of Development and Type of Product(s) / Solution(s)
7.2. Analysis of Product Landscape: Distribution by Current Status of Development and Type of Product(s) / Solution(s)
7.3. List of Products: Information on Regulatory Approval(s) and Therapeutic Application Area(s)
7.4. Analysis of Product Landscape: Distribution by Regulatory Approval(s) and Therapeutic Application Area(s)
7.5. List of Products: Information on Usage Period with respect to Pregnancy, Purpose(s) and End User(s)
7.6. Analysis of Product Landscape: Distribution by Usage Period with respect to Pregnancy, Purpose(s) and End User(s)
8. COMPANY HEALTH INDEXING
8.1. Company Health Indexing Methodology
8.2. Company Health Indexing Scoring
8.3. Company Health Indexing
9. VALUE PROPOSITION ANALYSIS
9.1. Overview and Methodology
9.2. Product-related Value
9.3. Value to Patients
9.4. Developer Value
9.5. Outreach-related Value
9.6. Concluding Remarks
10. COMPANY COMPETITIVENESS ANALYSIS
10.1. Overview and Methodology
10.2. Women’s Digital Health Solution Developers: Company Competitiveness Analysis
Section II: Analysis of Investments
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Overview
11.2. Analysis by Type of Funding
11.3. Analysis by Geography
11.4. Most Active Players and Popular Investors
11.5. Trends Across Various Funding Categories
11.6. Summary of Funding and Investments
Section III: Financial Analysis of Key Public Ventures
12. FINANCIAL ANALYSIS OF PUBLIC VENTURES
12.1. Fundamental Financial Analysis Overview
12.1.1. Financial Ratios (Interpretation Guide): Liquidity Ratios
12.1.2. Financial Ratios (Interpretation Guide): Financial and Business Risk Ratios
12.1.3. Financial Ratios (Interpretation Guide): Turnover / Efficiency Ratios
12.1.4. Financial Ratios (Interpretation Guide): Profitability Ratios
12.1.5. Financial Ratios (Interpretation Guide): Market Value Ratios
12.1.6. Financial Ratios (Interpretation Guide): Stability Ratios
12.2. Fundamental Financial Analysis: List of Companies
12.2.1. Case Study 1
12.2.2. Case Study 2
12.2.3. Case Study 3
12.3. Technical Financial Analysis Overview
12.3.1. Technical Indicators (Interpretation Guide): Candlestick Charts
12.3.2. Technical Indicators (Interpretation Guide): Moving Averages
12.3.3. Technical Indicators (Interpretation Guide): Bollinger Band®
12.3.4. Technical Indicators (Interpretation Guide): Relative Strength Index
12.3.5. Technical Indicators (Interpretation Guide): William’s R Analysis
12.3.6. Technical Indicators (Interpretation Guide): Moving Average Convergence Divergence
12.4. Technical Financial Analysis: List of Companies
12.4.1. Case Study 1
12.4.2. Case Study 2
12.4.3. Case Study 3
13. COMPANY PROFILES OF PUBLIC VENTURES
13.1. Bonzun
13.1.1. Key Highlights
13.1.1.1. Company Overview
13.1.1.2. Key Executives
13.1.1.3. Insights from Balance Sheet
13.1.1.4. Product / Service Portfolio
13.1.1.5. Recent Developments
13.1.2. Key Financial Details
13.1.2.1. Company Investments
13.1.2.2. Company Fundamentals
13.1.2.3. Company Technicals
13.2. HeraMED
13.2.1. Key Highlights
13.2.1.1. Company Overview
13.2.1.2. Key Executives
13.2.1.3. Insights from Balance Sheet
13.2.1.4. Product / Service Portfolio
13.2.1.5. Recent Developments
13.2.2. Key Financial Details
13.2.2.1. Company Investments
13.2.2.2. Company Fundamentals
13.2.2.3. Company Technicals
13.3. Sera Prognostics
13.3.1. Key Highlights
13.3.1.1. Company Overview
13.3.1.2. Key Executives
13.3.1.3. Insights from Balance Sheet
13.3.1.4. Product / Service Portfolio
13.3.1.5. Recent Developments
13.3.2. Key Financial Details
13.3.2.1. Company Investments
13.3.2.2. Company Fundamentals
13.3.2.3. Company Technicals
Section IV: Market Forecast and Opportunity Analysis
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Overview and Methodology
14.2. Global Women’s Digital Health Market, 2023-2035
14.3. Distribution Across Key Market Segments
14.3.1. Women’s Digital Health Market: Distribution by Type of Solution, 2023 and 2035
14.3.1.1. Women’s Digital Health Market for Applications / Software, 2023-2035
14.3.1.2. Women’s Digital Health Market for Devices, 2023-2035
14.3.1.3. Women’s Digital Health Market for Services, 2023-2035
14.3.2. Women’s Digital Health Market: Distribution by Therapeutic Application Area, 2023 and 2035
14.3.2.1. Women’s Digital Health Market for General Wellness, 2023-2035
14.3.2.2. Women’s Digital Health Market for Menstrual Cycle, 2023-2035
14.3.2.3. Women’s Digital Health Market for Reproductive Health / Fertility, 2023-2035
14.3.2.4. Women’s Digital Health Market for Fetal Health, 2023-2035
14.3.2.5. Women’s Digital Health Market for Pelvic Care, 2023-2035
14.3.3. Women’s Digital Health Market: Distribution by Key Geographical Regions, 2023 and 2035
14.3.3.1. Women’s Digital Health Market in North America, 2023-2035
14.3.3.2. Women’s Digital Health Market in Europe, 2023-2035
14.3.3.3. Women’s Digital Health Market in Asia-Pacific, 2023-2035
14.3.3.4. Women’s Digital Health Market in Latin America, 2023-2035
14.3.3.5. Women’s Digital Health Market in Middle East and North Africa, 2023-2035
14.4. Women’s Digital Health Market for Applications / Software, 2023-2035
14.4.1. Women’s Digital Health Market for Applications / Software: Distribution by Therapeutic Application Area, 2023 and 2035
14.4.1.1. Women’s Digital Health Applications / Software Market for General Wellness, 2023-2035
14.4.1.2. Women’s Digital Health Applications / Software Market for Menstrual Cycle, 2023-2035
14.4.1.3. Women’s Digital Health Applications / Software Market for Reproductive Health / Fertility, 2023-2035
14.4.1.4. Women’s Digital Health Applications / Software Market for Fetal Health, 2023-2035
14.4.1.5. Women’s Digital Health Applications / Software Market for Pelvic Care, 2023-2035
14.4.2. Women’s Digital Health Market for Applications / Software: Distribution by Key Geographical Regions, 2023 and 2035
14.4.2.1. Women’s Digital Health Applications / Software Market in North America, 2023-2035
14.4.2.2. Women’s Digital Health Applications / Software Market in Europe, 2023-2035
14.4.2.3. Women’s Digital Health Applications / Software Market in Asia-Pacific, 2023-2035
14.4.2.4. Women’s Digital Health Applications / Software Market in Latin America, 2023-2035
14.4.2.5. Women’s Digital Health Applications / Software Market in Middle East and North Africa, 2023-2035
14.5. Women’s Digital Health Market for Devices, 2023-2035
14.5.1. Women’s Digital Health Market for Devices: Distribution by Therapeutic Application Area, 2023 and 2035
14.5.1.1. Women’s Digital Health Devices Market for General Wellness, 2023-2035
14.5.1.2. Women’s Digital Health Devices Market for Menstrual Cycle, 2023-2035
14.5.1.3. Women’s Digital Health Devices Market for Reproductive Health / Fertility, 2023-2035
14.5.1.4. Women’s Digital Health Devices Market for Fetal Health, 2023-2035
14.5.1.5. Women’s Digital Health Devices Market for Pelvic Care, 2023-2035
14.5.2. Women’s Digital Health Market for Devices: Distribution by Key Geographical Regions, 2023 and 2035
14.5.2.1. Women’s Digital Health Devices Market in North America, 2023-2035
14.5.2.2. Women’s Digital Health Devices Market in Europe, 2023-2035
14.5.2.3. Women’s Digital Health Devices Market in Asia-Pacific, 2023-2035
14.5.2.4. Women’s Digital Health Devices Market in Latin America, 2023-2035
14.5.2.5. Women’s Digital Health Devices Market in Middle East and North Africa, 2023-2035
14.6. Women’s Digital Health Market for Services, 2023-2035
14.6.1. Women’s Digital Health Market for Services: Distribution by Therapeutic Application Area, 2023 and 2035
14.6.1.1. Women’s Digital Health Services Market for General Wellness, 2023-2035
14.6.1.2. Women’s Digital Health Services Market for Menstrual Cycle, 2023-2035
14.6.1.3. Women’s Digital Health Services Market for Reproductive Health / Fertility, 2023-2035
14.6.1.4. Women’s Digital Health Services Market for Fetal Health, 2023-2035
14.6.1.5. Women’s Digital Health Services Market for Pelvic Care, 2023-2035
14.6.2. Women’s Digital Health Market for Services: Distribution by Key Geographical Regions, 2023 and 2035
14.6.2.1. Women’s Digital Health Services Market in North America, 2023-2035
14.6.2.2. Women’s Digital Health Services Market in Europe, 2023-2035
14.6.2.3. Women’s Digital Health Services Market in Asia-Pacific, 2023-2035
14.6.2.4. Women’s Digital Health Services Market in Latin America, 2023-2035
14.6.2.5. Women’s Digital Health Services Market in Middle East and North Africa, 2023-2035
Section V: Key Acquisition Targets, Business Risk Assessment and Return on Investments
15. KEY ACQUISITION TARGETS
15.1. Overview and Methodology
15.2. List of Key Acquisition Targets – Company Strength
15.3. List of Key Acquisition Targets – Value Proposition
15.4. Key Acquisition Targets
16. BUSINESS RISK ASSESSMENT
16.1. Chapter Overview
16.2. Operations-related Risks
16.3. Product / Technology Risks
16.4. Business-related Risks
16.5. Financial / Asset-related Risks
16.6. Other Risks
17. RETURN ON INVESTMENTS
17.1. Overview and Methodology
17.2. Case Study
18. CONCLUSION
19. APPENDICES
Figure 5.1. Women’s Digital Health: Benefits of Digital Health Technologies
Figure 5.2. Women’s Digital Health: Key Application Areas of FemTech Industry
Figure 5.3. Women’s Digital Health: Type of Product(s) / Solution(s) and Key Industry Players
Figure 5.4. Women’s Digital Health: Key Marketed Products
Figure 5.5. Prominent Barriers to the Development and Success of Women’s Digital Health Solutions
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Type of Market
Figure 6.5. Innovator Landscape: Distribution by Number of Products
Figure 6.6. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution by Current Status of Development
Figure 7.2. Product Landscape: Distribution by Type of Product(s) / Solution(s)
Figure 7.3. Product Landscape: Distribution by Regulatory Approval(s)
Figure 7.4. Product Landscape: Distribution by Therapeutic Application Area(s)
Figure 7.5. Product Landscape: Distribution by Usage Period with respect to Pregnancy
Figure 7.6. Product Landscape: Distribution by Purpose(s)
Figure 7.7. Product Landscape: Distribution by End User(s)
Figure 9.1. Product-related Value: Distribution of Companies by Value Offered and Experience
Figure 9.2. Product-related Value: Distribution of Companies Offering High Value
Figure 9.3. Value to Patients: Distribution of Companies by Value Offered and Experience
Figure 9.4. Value to Patients: Distribution of Companies Offering Very High Value
Figure 9.5. Developer Value: Distribution of Companies by Value Offered and Experience
Figure 9.6. Developer Value: Distribution of Companies Offering High and Very High Value
Figure 9.7. Outreach-related Value: Distribution of Companies by Value Offered and Experience
Figure 9.8. Outreach-related Value: Distribution of Companies Offering Very High Value
Figure 9.9. Value Proposition Analysis: Concluding Remarks
Figure 10.1. Company Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 10.2. Company Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 10.3. Company Competitiveness Analysis: Small Companies based in North America, 2009-2016 (Peer Group III)
Figure 10.4. Company Competitiveness Analysis: Small Companies based in North America, 2017-2022 (Peer Group IV)
Figure 10.5. Company Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 10.6. Company Competitiveness Analysis: Small Companies based in Europe, 2010-2016 (Peer Group VI)
Figure 10.7. Company Competitiveness Analysis: Small Companies based in Europe, 2017-2021 (Peer Group VII)
Figure 10.8. Company Competitiveness Analysis: Large and Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 10.9. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World, 2011-2017 (Peer Group IX)
Figure 10.10. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World, 2018-2020 (Peer Group X)
Figure 11.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, Pre-2013-2022 (USD Million)
Figure 11.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 11.3. Funding and Investment Analysis: Distribution of Instances by Type of Venture Capital Funding
Figure 11.4. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5. Funding and Investment Analysis: Distribution of Amount Invested by Venture Capital Funding (USD Million)
Figure 11.6. Funding and Investment Analysis: Geographical Distribution of Funding Instances
Figure 11.7. Funding and Investment Analysis: Geographical Distribution of Amount Invested (USD Million)
Figure 11.8. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 11.9. Funding and Investment Analysis: Most Active Players by Amount Raised (USD Million)
Figure 11.10. Funding and Investment Analysis: Most Active Investors by Number of Instances
Figure 11.11. Awards / Grants: Cumulative Instances and Amount Invested (USD Million)
Figure 11.12. Awards / Grants: Global Distribution of Amount Invested (USD Million)
Figure 11.13. Awards / Grants: Most Active Investors
Figure 11.14. Crowd Funding: Cumulative Instances and Amount Invested (USD Million)
Figure 11.15. Crowd Funding: Global Distribution of Amount Invested (USD Million)
Figure 11.16. Seed Funding: Cumulative Instances and Amount Invested (USD Million)
Figure 11.17. Seed Funding: Global Distribution of Amount Invested (USD Million)
Figure 11.18. Seed Funding: Most Active Investors
Figure 11.19. Venture (Series A): Cumulative Instances and Amount Invested (USD Million)
Figure 11.20. Venture (Series A): Global Distribution of Amount Invested (USD Million)
Figure 11.21. Venture (Series A): Most Active Investors
Figure 11.22. Venture (Series B): Cumulative Instances and Amount Invested (USD Million)
Figure 11.23. Venture (Series B): Global Distribution of Amount Invested (USD Million)
Figure 11.24. Venture (Series B): Most Active Investors
Figure 11.25. Venture (Series C): Cumulative Instances and Amount Invested (USD Million)
Figure 11.26. Venture (Series C): Global Distribution of Amount Invested (USD Million)
Figure 11.27. Venture (Series C): Most Active Investors
Figure 11.28. Venture (Series D): Cumulative Instances and Amount Invested (USD Million)
Figure 11.29. Venture (Series D): Global Distribution of Amount Invested (USD Million)
Figure 11.30. Venture (Series D): Most Active Investors
Figure 11.31. Venture (Series E): Cumulative Instances and Amount Invested (USD Million)
Figure 11.32. Venture (Series E): Global Distribution of Amount Invested (USD Million)
Figure 11.33. Venture (Series E): Most Active Investors
Figure 11.34. Public Offering: Cumulative Instances and Amount Invested (USD Million)
Figure 11.35. Public Offering: Global Distribution of Amount Invested (USD Million)
Figure 11.36. Private Placement: Cumulative Instances and Amount Invested (USD Million)
Figure 11.37. Private Placement: Global Distribution of Amount Invested (USD Million)
Figure 11.38. Private Placement: Most Active Investors
Figure 11.39. Debt Financing: Cumulative Instances and Amount Invested (USD Million)
Figure 11.40. Debt Financing: Global Distribution of Amount Invested (USD Million)
Figure 11.41. Debt Financing: Most Active Investors
Figure 11.42. Capital Investments in Women’s Digital Health: Summary of Investments, 2011-2022
Figure 12.1. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (Bonzun)
Figure 12.2. Fundamental Financial Analysis: Liquidity Ratios, 2-years Trend (Bonzun)
Figure 12.3. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 2-years Trend (Bonzun)
Figure 12.4. Fundamental Financial Analysis: Profitability Ratios, 2-years Trend (Bonzun)
Figure 12.5. Fundamental Financial Analysis: Market Value and Stability Ratios, 2-years Trend (Bonzun)
Figure 12.6. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (HeraMED)
Figure 12.7. Fundamental Financial Analysis: Liquidity Ratios, 5-years Trend (HeraMED)
Figure 12.8. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 5-years Trend (HeraMED)
Figure 12.9. Fundamental Financial Analysis: Profitability Ratios, 5-years Trend (HeraMED)
Figure 12.10. Fundamental Financial Analysis: Market Value and Stability Ratios, 5-years Trend (HeraMED)
Figure 12.11. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (Sera Prognostics)
Figure 12.12. Fundamental Financial Analysis: Liquidity Ratios, 3-years Trend (Sera Prognostics)
Figure 12.13. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 3-years Trend (Sera Prognostics)
Figure 12.14. Fundamental Financial Analysis: Profitability Ratios, 3-years Trend (Sera Prognostics)
Figure 12.15. Fundamental Financial Analysis: Market Value and Stability Ratios, 3-years Trend (Sera Prognostics)
Figure 12.16. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (Bonzun)
Figure 12.17. Technical Analysis: 5-Day Moving Average (Bonzun)
Figure 12.18. Technical Analysis: 10-Day Moving Average (Bonzun)
Figure 12.19. Technical Analysis: 50-Day Moving Average (Bonzun)
Figure 12.20. Technical Analysis: Bollinger Band® (Bonzun)
Figure 12.21. Technical Analysis: Relative Strength Index (Bonzun)
Figure 12.22. Technical Analysis: Williams %R (Bonzun)
Figure 12.23. Technical Analysis: Moving Average Convergence Divergence (Bonzun)
Figure 12.24. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (HeraMED)
Figure 12.25. Technical Analysis: 5-Day Moving Average (HeraMED)
Figure 12.26. Technical Analysis: 10-Day Moving Average (HeraMED)
Figure 12.27. Technical Analysis: 50-Day Moving Average (HeraMED)
Figure 12.28. Technical Analysis: Bollinger Band® (HeraMED)
Figure 12.29. Technical Analysis: Relative Strength Index (HeraMED)
Figure 12.30. Technical Analysis: Williams %R (HeraMED)
Figure 12.31. Technical Analysis: Moving Average Convergence Divergence (HeraMED)
Figure 12.32. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (Sera Prognostics)
Figure 12.33. Technical Analysis: 5-Day Moving Average (Sera Prognostics)
Figure 12.34. Technical Analysis: 10-Day Moving Average (Sera Prognostics)
Figure 12.35. Technical Analysis: 50-Day Moving Average (Sera Prognostics)
Figure 12.36. Technical Analysis: Bollinger Band® (Sera Prognostics)
Figure 12.37. Technical Analysis: Relative Strength Index (Sera Prognostics)
Figure 12.38. Technical Analysis: Williams %R (Sera Prognostics)
Figure 12.39. Technical Analysis: Moving Average Convergence Divergence (Sera Prognostics)
Figure 13.1. Bonzun: Company Fundamentals
Figure 13.2. Bonzun: Company Technicals
Figure 13.3. HeraMED: Company Fundamentals
Figure 13.4. HeraMED: Company Technicals
Figure 13.5. Sera Prognostics: Company Fundamentals
Figure 13.6. Sera Prognostics: Company Technicals
Figure 14.1. Global Women’s Digital Health Market, 2023-2035 (USD Million)
Figure 14.2. Women’s Digital Health Market: Distribution by Type of Solution, 2023 and 2035
Figure 14.3. Women’s Digital Health Market for Applications / Software, 2023-2035 (USD Million)
Figure 14.4. Women’s Digital Health Market for Devices, 2023-2035 (USD Million)
Figure 14.5. Women’s Digital Health Market for Services, 2023-2035 (USD Million)
Figure 14.6. Women’s Digital Health Market: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.7. Women’s Digital Health Market for General Wellness, 2023-2035 (USD Million)
Figure 14.8. Women’s Digital Health Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.9. Women’s Digital Health Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.10. Women’s Digital Health Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.11. Women’s Digital Health Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.12. Women’s Digital Health Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.13. Women’s Digital Health Market in North America, 2023-2035 (USD Million)
Figure 14.14. Women’s Digital Health Market in Europe, 2023-2035 (USD Million)
Figure 14.15. Women’s Digital Health Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.16. Women’s Digital Health Market in Latin America, 2023-2035 (USD Million)
Figure 14.17. Women’s Digital Health Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.18. Women’s Digital Health Market for Applications / Software: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.19. Women’s Digital Health Applications / Software Market for General Wellness, 2023-2035 (USD Million)
Figure 14.20. Women’s Digital Health Applications / Software Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.21. Women’s Digital Health Applications / Software Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.22. Women’s Digital Health Applications / Software Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.23. Women’s Digital Health Applications / Software Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.24. Women’s Digital Health Market for Applications / Software: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.25. Women’s Digital Health Applications / Software Market in North America, 2023-2035 (USD Million)
Figure 14.26. Women’s Digital Health Applications / Software Market in Europe, 2023-2035 (USD Million)
Figure 14.27. Women’s Digital Health Applications / Software Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.28. Women’s Digital Health Applications / Software Market in Latin America, 2023-2035 (USD Million)
Figure 14.29. Women’s Digital Health Applications / Software Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.30. Women’s Digital Health Market for Devices: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.31. Women’s Digital Health Devices Market for General Wellness, 2023-2035 (USD Million)
Figure 14.32. Women’s Digital Health Devices Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.33. Women’s Digital Health Devices Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.34. Women’s Digital Health Devices Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.35. Women’s Digital Health Devices Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.36. Women’s Digital Health Market for Devices: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.37. Women’s Digital Health Devices Market in North America, 2023-2035 (USD Million)
Figure 14.38. Women’s Digital Health Devices Market in Europe, 2023-2035 (USD Million)
Figure 14.39. Women’s Digital Health Devices Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.40. Women’s Digital Health Devices Market in Latin America, 2023-2035 (USD Million)
Figure 14.41. Women’s Digital Health Devices Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.42. Women’s Digital Health Market for Services: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.43. Women’s Digital Health Services Market for General Wellness, 2023-2035 (USD Million)
Figure 14.44. Women’s Digital Health Services Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.45. Women’s Digital Health Services Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.46. Women’s Digital Health Services Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.47. Women’s Digital Health Services Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.48. Women’s Digital Health Market for Services: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.49. Women’s Digital Health Services Market in North America, 2023-2035 (USD Million)
Figure 14.50. Women’s Digital Health Services Market in Europe, 2023-2035 (USD Million)
Figure 14.51. Women’s Digital Health Services Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.52. Women’s Digital Health Services Market in Latin America, 2023-2035 (USD Million)
Figure 14.53. Women’s Digital Health Services Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 15.1. Key Acquisition Targets: Comparison based on Qualifying Parameters
Figure 16.1. Business Risk Analysis: Operations-related Risks
Figure 16.2. Business Risk Analysis: Product / Technology Risks
Figure 16.3. Business Risk Analysis: Business-related Risks
Figure 16.4. Business Risk Analysis: Financial / Asset-related Risks
Figure 16.5. Business Risk Analysis: Other Risks
Figure 17.1. Returns on Investment: Reported by Selected Stakeholders in Sera Prognostics and Historical Funding Activity
Figure 18.1. Concluding Landscape: North America
Figure 18.2. Concluding Landscape: Europe
Figure 18.3. Concluding Landscape: Asia-Pacific
Table 6.1. List of Innovators in Women’s Digital Health Market
Table 7.1. List of Products: Information on Current Status of Development and Type of Product(s) / Solution(s)
Table 7.2. List of Products: Information on Regulatory Approval(s) and Therapeutic Application Area(s)
Table 7.3. List of Products: Information on Usage Period with respect to Pregnancy, Purpose(s) and End User(s)
Table 8.1. Company Health Indexing
Table 9.1. Value Proposition Analysis: List of Top Six players
Table 10.1. Company Competitiveness Analysis: Scoring of Parameters
Table 12.1. Fundamental Financial Analysis: List of Companies
Table 12.2. Technical Financial Analysis: List of Companies
Table 13.1. Bonzun: Insights from Balance Sheet
Table 13.2. HeraMED: Insights from Balance Sheet
Table 13.3. Sera Prognostics: Insights from Balance Sheet
Table 15.1. List of Women’s Digital Health Key Acquisition Targets (Company Strength)
Table 15.2. List of Women’s Digital Health Key Acquisition Targets (Value Proposition)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Source 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499383/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES